1. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Issue 12 (22nd August 2013) Authors: Rosenstock, J.; Seman, L. J.; Jelaska, A.; Hantel, S.; Pinnetti, S.; Hach, T.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 12(2013:Dec.) Page Start: 1154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Issue 10 (14th July 2015) Authors: Rosenstock, J.; Jelaska, A.; Zeller, C.; Kim, G.; Broedl, U. C.; Woerle, H. J.; on behalf of the EMPA‐REG BASALTM trial investigators Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗